Skip to main content

Table 2 (abstract A66). Characteristics of total population and patients divided into subgroups. Results reported as frequency (%) or mean (standard deviation)

From: Proceedings of the 2019 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Annual Scientific Meeting

Variable All Patients (n = 2751) Patients w Inactive Disease (n = 1249) Patients w Active Disease (n = 1428)
SOCIODEMOGRAPHIC
 Age (years) 12.4 (4.7) 11.8 (4.8) 12.9 (4.6)
 Female 1675/2356 (71%) 723/1024 (71%) 929/1304 (71%)
 Race (White) 1885/2207 (85%) 824/970 (85%) 1045/1216 (86%)
 Insurance Status (Private) 1536/1769 (87%) 713/812 (88%) 814/946 (86%)
CLINICAL CHARACTERISTICS
 Disease Duration (months) 68.1 (49.1) 69.0 (48.4) 67.2 (49.4)
 ILAR Subtype
  Polyarticular, RF (-) 790 (29%) 350 (28%) 420 (29%)
  Oligoarticular, persistent 768 (28%) 417 (33%) 330 (23%)
  Enthesitis related arthritis 332 (12%) 115 (9%) 207 (14%)
  Oligoarticular, extended 286 (10%) 138 (11%) 136 (10%)
  Psoriatic arthritis 184 (7%) 61 (5%) 121 (8%)
  Systemic arthritis 174 (6%) 87 (7%) 83 (6%)
  Polyarticular, RF (+) 157 (6%) 55 (4%) 100 (7%)
  Undifferentiated 54 (2%) 25 (2%) 27 (2%)
  ANA Positive 1339 (49%) 611 (49%) 691 (49%)
DISEASE ACTIVITY MEASURES
 Active Uveitis 133/2393 (6%) 0 129/1286 (10%)
 Systemic Features 21 (<1%) 0 21 (1%)
 Morning Stiffness > 15 min 1934/2389 (81%) 0 452/1303 (35%)
 Elevated ESR / CRP 204 (7%) / 139 (5%) 0 204 (14%) / 139 (10%)
 Active Joint Count 0.9 (2.0) 0 1.8 (2.5)
 MD Global Assessment 1.0 (1.4) 0.03 (0.1) 1.8 (1.5)
PATIENT-REPORTED MEASURES
 Patient Global Assessment (0-10) 1.7 (2.3) 0.74 (1.5) 2.6 (2.5)
 Pain Score (0-10) 2 (2.5) 0.8 (1.5) 2.9 (2.8)
 CHAQ 0.24 (0.44) 0.11 (0.26) 0.36 (0.52)
MEDICATIONS
 Non-biologic DMARDs 1059 (38%) 399 (32%) 640 (45%)
  Methotrexate 914 (86%) 350 (88%) 549 (86%)
  Leflunomide 68 (6%) 24 (6%) 43 (7%)
  Sulfasalazine 51 (5%) 16 (4%) 34 (5%)
  Hydroxychloroquine 43 (4%) 7 (2%) 34 (5%)
  Other 14 (1%) 5 (1%) 10 (2%)
  More than one 33 (3%) 3 (<1%) 30 (5%)
 Biologic DMARDs 1101 (40%) 434 (35%) 684 (48%)
  All Anti-TNF 863 (31%) 350 (28%) 498 (35%)
   Etanercept 420 (38%) 191 (44%) 223 (33%)
   Adalimumab 331 (30%) 125 (29%) 202 (30%)
   Infliximab 105 (10%) 32 (7%) 68 (10%)
   Certolizumab 9 (<1%) 5 (1%) 4 (<1%)
   Golimumab 8 (<1%) 3 (<1%) 5 (<1%)
  Tocilizumab 97 (9%) 32 (7%) 64 (9%)
  Abatacept 80 (7%) 20 (5%) 60 (9%)
  Anakinra 23 (2%) 13 (3%) 9 (1%)
  Canakinumab 21 (2%) 12 (3%) 8 (1%)
  Rituximab 6 (<1%) 1 (<1%) 4 (<1%)
  Tofacitinib 4 (<1%) 0 4 (<1%)
  Other 2 (<1%) 2 (<1%) 0
  More than one 5 (<1%) 2 (<1%) 3 (<1%)
 NSAIDs
 Daily 770 (28%) 204 (16%) 551 (29%)
  Intermittent 345 (13%) 150 (12%) 195 (14%)
 Glucocorticoids
  Intra-articular 201 (7%) 46 (4%) 147 (10%)
  Systemic 84 (3%) 17 (1%) 63 (4%)
  Ophthalmic 119 (4%) 19 (2%) 94 (7%)
  1. A chi-square or t-test was performed to compare characteristics of patients with inactive and active disease. Results with p < 0.05 are bolded